Update
$Marker Therapeutics (MRKR.US)$ Reuters· just
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
